| Carbidopa and L-dopa prodrugs and their use to treat Parkinson's disease |
2023-8-04 |
2023-8-24 |
|
| Modulators of the integrated stress pathway |
2023-6-20 |
2023-7-13 |
|
| Anti-EGFR antibodies and antibody drug conjugates |
2023-6-08 |
2023-7-06 |
|
| Levodopa and carbidopa intestinal gel and methods of use |
2023-5-29 |
2023-6-22 |
|
| Methods of Administering Elagolix |
2023-5-05 |
2023-8-31 |
|
| Modulators of the integrated stress pathway |
2023-4-28 |
2023-5-18 |
|
| Method of administering upadacitinib to avoid adverse drug interactions and … |
2023-3-28 |
2023-7-27 |
|
| Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 … |
2023-3-28 |
2023-8-17 |
|
| Modulators of the integrated stress pathway |
2023-3-23 |
2023-4-27 |
|
| Methods for treating relapsing forms of multiple sclerosis |
2023-3-10 |
2023-5-30 |
|
| Modulators of the integrated stress pathway |
2023-3-07 |
2023-4-06 |
|
| PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[ … |
2023-3-01 |
2023-7-13 |
|
| PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[ … |
2023-3-01 |
2023-7-20 |
|
| PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[ … |
2023-3-01 |
2023-8-31 |
|
| Levodopa and carbidopa intestinal gel and methods of use |
2023-2-16 |
2023-4-25 |
|
| Pharmaceutical formulations for treating endometriosis, uterine fibroids, … |
2023-2-13 |
2023-8-17 |
|
| Methods of treatment of diseases in which il-13 activity is detrimental using … |
2023-2-03 |
2023-7-13 |
|
| Anti-αlfa-4-βeta-7 antibodies |
2023-1-31 |
2023-2-06 |
|
| Anti-EGFR antibody drug conjugate formulations |
2023-1-27 |
2023-3-02 |
|
| Protein tyrosine phosphatase inhibitors and methods of use thereof |
2023-1-24 |
2023-4-18 |
|
| 1,3,4,7-tetrahydro-2h-pyrrolo [3',2':5,6] pyrido[2,3-b] [1,4] oxazepine bc1-2 … |
2023-1-20 |
2023-7-27 |
|
| Protein tyrosine phosphatase inhibitors and methods of use thereof |
2022-12-27 |
2023-4-11 |
|
| Prodrug modulators of the integrated stress pathway |
2022-12-27 |
2023-3-22 |
|
| Dosing regimens for use in treating relapsed and refractory multiple myeloma … |
2022-12-08 |
2023-6-15 |
|
| Anti-dll4/vegf dual variable domain immunoglobulin and uses thereof |
2022-12-01 |
2023-3-14 |
|
| Protein tyrosine phosphatase inhibitors and methods of use thereof |
2022-11-10 |
2023-5-19 |
|
| Treatment of major depressive disorder |
2022-10-28 |
2023-5-18 |
|
| Anti-amyloid beta antibodies and methods of using the same |
2022-10-28 |
2023-6-29 |
|
| Subcutaneously administered treatments for advanced parkinson's disease |
2022-10-27 |
2023-6-01 |
|
| Monoclonal antibodies against amyloid beta protein and uses thereof |
2022-10-27 |
2022-12-01 |
|
| Anti-hemojuvelin (hjv) antibodies for treating anemia of chronic disease |
2022-10-20 |
2022-12-01 |
|
| Methods of treating diabetic kidney disease |
2022-10-11 |
2022-12-01 |
|
| Treating spondyloarthritic conditions with upadacitinib |
2022-10-05 |
2023-4-13 |
|
| Topical formulation |
2022-9-28 |
2022-10-27 |
|
| ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE |
2022-9-26 |
2022-12-13 |
|
| ANTI-EGFR ANTIBODY-DRUG CONJUGATES |
2022-9-09 |
2022-9-30 |
|
| Solid pharmaceutical compositions for treating hcv |
2022-8-26 |
2022-11-30 |
|
| Process of making apoptosis-inducing agents |
2022-8-25 |
2023-3-02 |
|
| Protein tyrosine phosphatase targeting ligands |
2022-8-10 |
2023-2-16 |
|
| Nicotinamide ripk1 inhibitors |
2022-8-08 |
2023-2-16 |
|
| Methods for treating HCV |
2022-7-29 |
2022-8-25 |
|
| Anti-ccr8 antibodies |
2022-7-27 |
2023-2-16 |
|
| Crystal forms |
2022-7-07 |
2022-9-13 |
|
| Bromodomain inhibitors |
2022-6-30 |
2023-5-25 |
|
| Protein tyrosine phosphatase inhibitors and methods of use thereof |
2022-6-16 |
2023-1-19 |
|
| Modulators of the integrated stress pathway |
2022-6-14 |
2023-5-11 |
|
| Anti-CD40 antibodies and uses thereof |
2022-6-10 |
2022-6-30 |
|
| Anti-cd98 antibodies and antibody drug conjugates |
2022-6-08 |
2023-5-04 |
|
| Methods of treating acute myeloid leukemia and managing cytopenia |
2022-6-07 |
2023-1-05 |
|
| Devices and methods for delivering a beneficial agent to a user |
2022-5-20 |
2022-12-01 |
|
| Isolation and purification of anti-il-13 antibodies using protein a affinity … |
2022-5-17 |
2022-10-27 |
|
| Venetoclax dosing regimens for use in treating myelodysplastic syndromes in … |
2022-5-10 |
2022-11-17 |
|
| Medication packaging and dispensing system |
2022-5-10 |
2022-8-25 |
|
| Dosing regimens for use in the treatment of myelofibrosis and mpn-related … |
2022-5-04 |
2023-1-20 |
|
| Anti-c-met antibody drug conjugates |
2022-4-29 |
2022-12-01 |
|
| IL-1 Binding Proteins |
2022-4-29 |
2023-4-13 |
|
| Methods of treating crohn's disease and ulcerative colitis |
2022-4-28 |
2023-1-31 |
2023-1-31 |
| Anti-cd98 antibodies and antibody drug conjugates |
2022-4-27 |
2023-4-20 |
|
| Subcutaneously administered treatments for advanced parkinson's disease |
2022-4-25 |
2023-4-27 |
|
| Macrocyclic mcl-1 inhibitors and methods of use |
2022-4-22 |
2022-8-18 |
|
| Elagolix Sodium Compositions and Processes |
2022-4-14 |
2022-10-13 |
|
| PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[ … |
2022-4-11 |
2022-8-11 |
|
| Cocrystals of upadacitinib |
2022-4-07 |
2022-10-13 |
|
| Methods of treatment of non-small-cell lung carcinoma using telisotuzumab … |
2022-4-06 |
2022-10-13 |
|
| Methods of treating Crohn's disease and ulcerative colitis |
2022-4-01 |
2023-3-21 |
2023-3-21 |
| Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses … |
2022-3-23 |
2023-6-15 |
|
| Enzyme compositions with reduced viral and microbial contamination |
2022-3-21 |
2022-7-07 |
|
| Bromodomain Inhibitors |
2022-3-11 |
2023-3-30 |
|
| Anti-egfr antibody drug conjugates |
2022-3-08 |
2023-4-13 |
|
| System and method of multi-drug delivery |
2022-2-27 |
2022-4-01 |
|
| Monoclonal antibodies against amyloid beta protein and uses thereof |
2022-2-24 |
2022-3-17 |
|
| Anti-cd40 antibodies and their uses |
2022-2-18 |
2022-5-09 |
|
| Modulators of the integrated stress pathway |
2022-2-11 |
2022-3-03 |
|
| PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[ … |
2022-2-09 |
2022-9-08 |
|
| Macrocyclic MCL-1 Inhibitors and Methods of Use |
2022-2-03 |
2023-6-15 |
|
| Methods of administrating elagolix |
2022-1-28 |
2023-2-02 |
|
| Systems and methods for identifying protein aggregates in biotherapeutics |
2022-1-25 |
2022-10-13 |
|
| Composition and method for the diagnosis and treatment of iron-related … |
2022-1-24 |
2022-2-17 |
|
| Anti-egfr antibody-drug conjugates |
2022-1-20 |
2022-11-01 |
|
| Novel tricyclic compounds |
2022-1-14 |
2023-3-16 |
|
| Methods of treating crohn's disease and ulcerative colitis |
2022-1-06 |
2022-7-14 |
|
| Extended release upadacitinib formulations |
2021-12-29 |
2022-7-07 |
|
| Anti-ox40 antibodies and their uses |
2021-12-23 |
2022-4-14 |
|
| Composition and method for diagnosis and treatment of diseases associated with … |
2021-12-22 |
2022-1-27 |
|
| Bicyclic pyrazole bruton's tyrosine kinase inhibitors |
2021-12-16 |
2022-7-07 |
|
| MODULATORS OF THE INTEGRATED STRESS PATHWAY |
2021-11-30 |
2021-12-30 |
|
| Automatic injection device |
2021-11-19 |
2022-10-06 |
|
| Glucocorticoid receptor agonist and immunoconjugates thereof |
2021-11-19 |
2021-12-16 |
|
| APOPTOSIS-INDUCING AGENTS THAT MAY BE USED TO TREAT CANCER AND IMMUNE AND … |
2021-11-19 |
2023-2-15 |
|
| Methods of treating heavy menstrual bleeding |
2021-11-18 |
2022-3-17 |
|
| Bromodomain inhibitor |
2021-11-10 |
2022-2-08 |
|
| Monoclonal antibodies against rgm a protein and uses thereof |
2021-11-05 |
2022-3-08 |
|
| Bispecific binding molecules |
2021-11-01 |
2022-9-29 |
|
| MODULATORS OF THE INTEGRATED STRESS PATHWAY |
2021-11-01 |
2022-5-31 |
|
| Substituted cyclolakyls as modulators of the integrated stress pathway |
2021-10-28 |
2021-12-01 |
|
| Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune … |
2021-10-17 |
2021-12-01 |
|
| Methods for Treating HCV |
2021-9-24 |
2022-9-15 |
|
| Nuclear receptor modulators |
2021-9-15 |
2021-10-14 |
|
| Protein tyrosine phosphatase inhibitors and methods of use thereof |
2021-9-10 |
2022-3-17 |
|
| Carbidopa and l-dopa prodrugs and methods of use |
2021-8-31 |
2022-1-04 |
|